Background-Cardiosphere-derived cells (CDCs) are an attractive cell type for tissue regeneration, and autologous CDCs are being tested clinically. However, autologous therapy necessitates patient-specific tissue harvesting and cell processing, with delays to therapy and possible variations in cell potency. The use of allogeneic CDCs, if safe and effective, would obviate such limitations. We compared syngeneic and allogeneic CDC transplantation in rats from immunologically-mismatched inbred strains. Methods and Results-In vitro, CDCs expressed major histocompatibility complex class I but not class II antigens or B7 costimulatory molecules. In mixed-lymphocyte cocultures, allogeneic CDCs elicited negligible lymphocyte proliferation and inflammatory cytokine secretion. In vivo, syngeneic and allogeneic CDCs survived at similar levels in the infarcted rat heart 1 week after delivery, but few syngeneic (and even fewer allogeneic) CDCs remained at 3 weeks. Allogeneic CDCs induced a transient, mild, local immune reaction in the heart, without histologically evident rejection or systemic immunogenicity. Improvements in cardiac structure and function, sustained for 6 months, were comparable with syngeneic and allogeneic CDCs. Allogeneic CDCs stimulated endogenous regenerative mechanisms (cardiomyocyte cycling, recruitment of c-kit ϩ cells, angiogenesis) and increased myocardial vascular endothelial growth factor, insulin-like growth factor-1, and hepatocyte growth factor equally with syngeneic CDCs. Conclusions-Allogeneic CDC transplantation without immunosuppression is safe, promotes cardiac regeneration, and improves heart function in a rat myocardial infarction model, mainly through stimulation of endogenous repair mechanisms. The indirect mechanism of action rationalizes the persistence of benefit despite the evanescence of transplanted cell survival. This work motivates the testing of allogeneic human CDCs as a potential off-the-shelf product for cellular cardiomyoplasty. (Circulation. 2012;125:100-112.)
C ell transplantation has emerged as a promising therapeutic strategy for acute or chronic ischemic cardiomyopathy. 1, 2 Multiple candidate cell types have been used in humans in efforts to repair or regenerate the injured heart either directly (through formation of new transplanted tissue) or indirectly, including skeletal myoblasts, bone marrowderived cells, and, more recently, heart-derived cells. 2, 3 During the first decade of cell therapy for heart disease, the vast majority of clinical trials were conducted with autologous cells. This approach avoids immunologic rejection but necessitates patient-specific tissue harvesting, cell processing, and quality control, imposing significant logistic, economic, and timing constraints. In addition, cell efficacy may be undermined by donor age and comorbidities. 4 The use of allogeneic cells, if safe and effective, would obviate such limitations, enabling the generation of highly standardized off-the-shelf cell products. The obvious disadvantage is the risk of immune rejection, which may limit effectiveness regardless of whether it poses safety hazards. Nevertheless, because the vast majority of the observed functional benefit is attributable to indirect pathways even with heart-derived cells, 5, 6 rejection of allogeneic cells may not be an issue if it occurs after the cells have exerted their beneficial paracrine effects and if the resulting benefits are durable. and mobilize pathways of endogenous repair and regeneration, resulting in sustained functional benefit. For the first time, we characterize the in vitro immunologic properties of heart-derived stem cells, monitor host immune system kinetics (leukocyte infiltration, inflammatory cytokine secretion, development of cellular/humoral memory response) and transplanted cell survival, and quantify functional effects after myocardial infarction (MI) in an immunologicallymismatched rat model of allogeneic CDC transplantation.
Methods
An expanded Methods section is available in the online-only Data Supplement.
Experimental Animals
To create a stringent model of allogeneic cell transplantation, we used rats from highly-inbred, immunologically-divergent strains characterized by complete mismatch of major histocompatibility complex (MHC) antigens. Male Wistar-Kyoto (WKY) rats (MHC haplotype, RTI l ) were used as CDC donors; female WKY and Brown Norway (BN) rats (MHC haplotype, RTI n ) were used as syngeneic and allogeneic recipients, respectively. In a model of xenogeneic transplantation used as a positive control for immune rejection, human CDCs (hCDCs) were transplanted into BN rats. Sample sizes for each experiment are listed in Table I in the online-only Data Supplement. All experimental protocols were approved by the Institutional Animal Care and Use Committee.
Cell Culture
Rat CDCs (rCDCs) were expanded from 8-week old male WKY rat hearts. hCDCs were expanded from endomyocardial biopsies or myocardial samples obtained from adult male patients during clinically indicated procedures after informed consent was given. Patient characteristics are presented in Table II in the online-only Data Supplement. CDCs were cultured as described. 7, 8 All experiments were performed with CDCs at passage 1. In a subset of experiments, CDCs were lentivirally transduced to express green fluorescent protein (GFP) to track transplanted cell fate by histology.
Flow Cytometry
Flow cytometry was performed to evaluate surface expression of MHC class I, MHC class II, and costimulatory molecules (CD80, CD86) in hCDCs and rCDCs under baseline conditions and after stimulation with interferon-␥ (IFN-␥). In addition, we characterized the general phenotype of CDCs (expression of CD105, c-Kit, CD90, CD31, CD45, CD140b, discoidin domain-containing receptor 2, and ␣-smooth muscle actin; antibodies listed in Table III in the onlineonly Data Supplement).
Mixed-Lymphocyte Reactions
The in vitro immunogenicity of CDCs was assessed by 1-way mixed-lymphocyte reactions. Mitomycin-inactivated stimulating rCDCs and hCDCs were cocultured with responder lymphocytes for 5 days. Responder cell proliferation was assessed by BrdU incorporation. The following experimental conditions were tested: rCDCs cocultured with WKY lymphocytes (syngeneic coculture), rCDCs cocultured with BN lymphocytes (allogeneic coculture), and hCDCs cocultured with BN lymphocytes (xenogeneic coculture). Alloreactive and xenoreactive lymphocyte proliferation is presented as relative proliferative response normalized to syngeneic lymphocyte proliferation (stimulation index). The cell-free supernatant of the cocultures was collected, and the levels of secreted IFN-␥, interleukin (IL)-1b, IL-13, IL-4, IL-5, KC/GRO (Chemokine [C-X-C motif] ligand 1), tumor necrosis factor-␣, and IL-2 were measured by electrochemiluminescence and ELISA.
MI and Cell Injection
Female WKY and BN rats (8 -10 week old) underwent permanent ligation of the left anterior descending coronary artery. CDCs (2 million suspended in 120 L PBS) or vehicle were injected intramyocardially at 4 sites along the periphery of the infarct. Five permutations were investigated: rCDCs injected into WKY hearts (syngeneic group), rCDCs injected into BN hearts (allogeneic group), hCDCs injected into BN hearts (xenogeneic group), vehicle injected into WKY hearts (control group a), and vehicle injected into BN hearts (control group b). Two control groups were used to confirm that both rat strains responded similarly to MI. Data for perioperative and longer-term mortality are presented in Table IV in the online-only Data Supplement. To monitor proliferation of both transplanted and endogenous cells, a subset of animals were injected intraperitoneally with BrdU daily for either the first week or the second and third weeks after MI.
Echocardiography
Echocardiography was performed to assess global cardiac function 6 hours (baseline), 3 weeks, 3 months, and 6 months after surgery. Fractional area change, left ventricular ejection fraction, and fractional shortening were measured.
Quantification of Engraftment by Real-Time Polymerase Chain Reaction
To monitor transplanted cell survival 1 and 3 weeks after MI, male cells were injected into female rats, and absolute cell engraftment was quantified with the use of species-specific SRY gene primers.
Histology
Rats were euthanized 1 week, 3 weeks, and 6 months after treatment. Hearts were cryosectioned and fixed with 4% paraformaldehyde. Quantitative morphometric analysis with Masson trichrome staining was performed to quantify scar size, infarcted wall thickness, and left ventricular remodeling. To evaluate immune rejection, sections stained with hematoxylin and eosin were evaluated in a blinded manner by a cardiac pathologist (D.L); in addition, immunostaining against immune cell markers was performed. Differentiation of CDCs, incidence of cycling host myocytes, recruitment of endogenous progenitors, and vessel density in the border zone were evaluated by immunohistochemistry (antibodies listed in Table III in the online-only Data Supplement).
Assessment of Systemic Immunogenicity and Development of Memory Immune Response
To assess systemic immunogenicity, levels of circulating inflammatory cytokines (IFN-␥, IL-1b, IL-13, IL-4, IL-5, KC/GRO, and tumor necrosis factor-␣) were quantified by electrochemiluminescence in rat sera from recipients of syngeneic, allogeneic, and xenogeneic CDCs and controls.
To assess humoral memory immune response, recipient rat sera were isolated 1 and 3 weeks after transplantation, and levels of circulating alloreactive and xenoreactive anti-donor IgG and IgM antibodies were quantified by flow cytometry.
To evaluate cellular memory immune response, spleens from allogeneic recipients were harvested 3 weeks after transplantation. Lymphocytes were isolated, and their reactivity against allogeneic donor cells by 1-way mixed-lymphocyte reactions was compared with that of naïve lymphocytes. The cell-free supernatant of the cocultures was collected, and the levels of secreted IFN-␥, IL-1b, IL-13, IL-4, IL-5, KC/GRO, tumor necrosis factor-␣, and IL-2 were measured by electrochemiluminescence and ELISA. 5 minutes, 1 day, 4 days, 7 days, and 21 days after MI. Protein was extracted and Western blots were performed as described 5 with the antibodies listed in Table III in the online-only Data Supplement.
Statistical Analysis
Results are presented as meansϮSEM. Normality of data was tested by use of the Shapiro-Wilk test, and equality of variances was tested with the Levene test. If normality of data and equality of variances were established, statistical significance was determined by 1-way ANOVA followed by the Bonferroni post hoc test. If normality of data or equality of variances could not be confirmed, statistical significance was determined by the Kruskal-Wallis test followed by the Dunn post hoc test. Linear mixed-effects models were used to compare the repeated measurements of cardiac function across groups. The outcome was the dependent variable; treatment group and time were the fixed effects; and an unstructured trend in time was assumed. Correlation in data from the same animal was taken into account by a random effect at the rat level. Categorical data were tested by the Fisher exact test. Differences between 2 groups were tested with the Mann-Whitney U test. Differences were considered significant when PϽ0.05.
Results

Characterization of CDC Antigens Including MHC and Costimulatory Molecules
Consistent with previous characterizations, 7,9 flow cytometry revealed that both rCDCs and hCDCs are naturally heterogeneous cell populations of nonhematological origin (CD45 Ϫ ) that are positive for CD105; subgroups positive for c-kit or CD90 are consistent with cardiac progenitor and cardiac mesenchymal fractions, respectively, whereas Ͻ4% of cells are positive for fibroblast (discoidin domain-containing receptor 2) or myofibroblast (␣-smooth muscle actin) markers ( Figure 1A ). With regard to immune antigens, both rCDCs and hCDCs express MHC class I but not MHC class II surface antigens or CD80/CD86 costimulatory molecules under baseline conditions ( Figure 1B) . Incubation with IFN-␥ upregulated MHC class I and MHC class II expression (but not costimulatory molecule expression) in a time-dependent manner ( Figure 1B and 1C) . The observed baseline immuno- phenotype of CDCs renders them attractive for allogeneic applications. Expression of MHC class I antigens is important because it protects cells from natural killer cell-mediated deletion, 10 whereas lack of expression of MHC class II antigens allows CDCs to escape direct recognition from CD4 ϩ T helper cells. MHC class I antigens may activate effector T cells, but in the absence of costimulatory molecules, a secondary signal would not engage, theoretically leaving T cells anergic. 11
Allogeneic CDCs Exhibit Negligible In Vitro Immunogenicity
One-way mixed-lymphocyte reaction experiments revealed that allogeneic rCDCs elicit negligible lymphocyte proliferation, comparable to that seen with syngeneic CDCs. On the other hand, xenogeneic hCDCs induce a strong proliferative response (Figure 2A and 2B). Levels of proinflammatory (IFN-␥, tumor necrosis factor-␣, IL-1b, IL-2, KC/GRO) and antiinflammatory (IL-5, IL-13, IL-4) cytokines were comparable in syngeneic and allogeneic coculture supernatants. Conversely, in the xenogeneic setting, secretion of all inflammatory cytokines was markedly increased, indicating significant activation of responder lymphocytes ( Figure 2C ).
Limited Survival of Allogeneic and Syngeneic CDCs After Transplantation
Two million male syngeneic, allogeneic, or xenogeneic CDCs were implanted into the ischemic myocardium of female rats immediately after left anterior descending artery ligation. Quantitative polymerase chain reaction with the male SRY gene as target revealed that engraftment of allogeneic and syngeneic CDCs is similar 1 week after MI ( Figure 3C ). Three weeks after MI, cell survival decreases markedly (to Ͻ1% of cells transplanted) in both groups, but the residual number of surviving cells is higher after syngeneic transplantation ( Figure 3D ). These results indicate that allogeneic CDCs are cleared more rapidly than syngeneic CDCs between days 8 and 21 after delivery. On the other hand, the vast majority of xenogeneic CDCs are rejected within 1 week of transplantation ( Figure 3C ), with no surviving cells detectable 3 weeks after MI ( Figure 3D ). The observed prompt rejection of xenogeneic CDCs in immunocompetent hosts echoes previous findings. 12
Allogeneic and Syngeneic CDCs Exert Comparable and Sustained Beneficial Effects on Infarcted Heart Structure and Function
Morphometric analysis of explanted hearts 3 weeks after MI showed severe left ventricular chamber dilatation and infarct wall thinning in animals in the xenogeneic and control groups ( Figure 4A ). In contrast, the syngeneic and allogeneic groups exhibited smaller scar size, increased infarcted wall thickness, and attenuation of left ventricular remodeling ( Figure  4A -4C). Scar size and infarcted wall thickness did not differ among animals treated with syngeneic or allogeneic CDCs, suggesting similar favorable treatment effects in these 2 groups.
To investigate whether allogeneic cell transplantation offers functional benefit, global cardiac function was assessed by echocardiography. At baseline, fractional area change, left ventricular ejection fraction, and fractional shortening did not differ among treatment groups, indicating similar degrees of initial injury. Over the first 3 weeks after MI, indexes of function did not improve in the xenogeneic and control groups, whereas fractional area change, left ventricular ejection fraction, and fractional shortening all rose significantly, and to similar degrees, in the syngeneic and allogeneic groups. Notably, the functional benefit observed at 3 weeks persisted at 6 months ( Figure 4D-4G ). Thus, despite lower engraftment at 3 weeks, allogeneic CDCs pack the same punch functionally and structurally as syngeneic CDCs.
Allogeneic CDCs Are Hypoimmunogenic In Vivo
To evaluate the spatiotemporal development of immune rejection in the scar, border zone, and remote myocardium, hematoxylin and eosin-stained sections obtained at 1 week, 3 weeks, and 6 months after treatment were evaluated with the International Society of Heart and Lung Transplantation grading system (used in clinical practice to diagnose rejection; Figure 5 ) and a homemade, more descriptive grading system (Tables V-VII Table VI in the online-only Data Supplement) after MI. The infiltrating cells were localized within interstitial and perivascular spaces ( Figure 5A ), but no foci of myocyte damage could be detected, even with xenogeneic CDCs. The remote myocardium was consistently clear of rejection, in agreement with previously observed homing of transplanted CDCs to the infarct and peri-infarct areas. 5, 7 Although clinically useful in the assessment of transplant rejection, detection of small foci of rejection by hematoxylin and eosin staining is complicated in a post-MI setting by the natural inflammatory response to the ischemic insult. Because our quantitative polymerase chain reaction data revealed disproportionate loss of allogeneic CDCs at 3 weeks, we performed extensive immunostaining to define the identity of the infiltrating inflammatory cells ( Figure 6 ). In the allogeneic setting, immunohistochemistry revealed rare events of rejection; a few small and sparse infiltrates (some around transplanted cells [ Figure 6A ]) were detected 3 weeks after treatment in the infarct and peri-infarct areas, made up primarily of CD3 ϩ T lymphocytes (with equal contributions of CD8 ϩ T cytotoxic and CD4 ϩ T helper subpopulations) and, to a lesser extent, CD45RA ϩ B lymphocytes and CD11c ϩ dendritic cells. The similar amounts of CD4 ϩ and CD8 ϩ T lymphocytes and the presence of dendritic cells in the grafts hint at a more prominent role of the indirect pathway of allorecognition in the immune rejection of trans- Table I in planted cells. It is plausible that antigens shed by apoptotic donor CDCs are phagocytosed by host antigen-presenting cells (eg, dendritic cells) and subsequently presented to CD4 ϩ cells, thus activating the immune cascade; however, a role for the direct pathway of allorecognition cannot be ruled out. 13 Importantly, the increased lymphohistiocytic infiltration observed at 3 weeks was much lower than that seen with xenogeneic transplantation ( Figure 6D ) and had completely subsided by 6 months ( Figure IV and Table VII in the online-only Data Supplement). The higher infiltration of macrophages (which did not localize within the infiltrates but were evenly dispersed along the infarct) detected at 1 and 3 weeks after MI in the xenogeneic and control groups was consistent with the larger infarct size observed in those groups.
To assess the possibility of systemic immunogenicity of CDC transplantation, levels of circulating inflammatory cytokines were measured in rat serum samples obtained 3 weeks after treatment. Quantification of inflammatory cytokines demonstrated comparable levels of circulating proinflammatory (IFN-␥, tumor necrosis factor-␣, IL-1b, KC/GRO) and antiinflammatory (IL-5, IL-13, IL-4) cytokines in the syngeneic, allogeneic, and control groups. Conversely, in the xenogeneic setting, the circulating levels of IFN-␥, IL-1␤, IL-13, and IL-4 were markedly increased ( Figure I in the online-only Data Supplement). Taken together, these data indicate that the systemic inflammatory response observed after xenogeneic transplantation did not occur in the allogeneic setting.
Allogeneic CDCs Elicit a Cellular But Not a Humoral Immune Memory Response
To assess the development of cellular memory immune response after allogeneic CDC transplantation, the alloreactivity of lymphocytes isolated from spleens of allogeneic recipients 3 weeks after transplantation was assessed by 1-way mixed-lymphocyte reactions. Lymphocytes from sensitized animals exhibited higher proliferation after coculture with allogeneic CDCs compared with naïve lymphocytes or syngeneic cocultures ( Figure  IIIA the online-only Data Supplement). These findings, indicative of a T-cell memory response, are in accordance with the immunohistochemistry data showing a predominant role of T cells in the sparse mononuclear infiltrates observed 3 weeks after allogeneic transplantation ( Figure 6C and 6D) . We did not test whether the intensity of the cellular memory response diminishes with time, as reported in studies of allogeneic mesenchymal cell transplantation. 14 To assess the development of a humoral memory response, recipient rat sera obtained 1 and 3 weeks after transplantation A and B , Immunohistochemistry revealed small, sparse interstitial infiltrates in the proximity of some allogeneic cardiosphere-derived cells (CDCs) 3 weeks after transplantation, whereas large infiltrates could be detected in the xenogeneic setting. Infiltrates comprised mainly CD3 ϩ T lymphocytes (with equal contributions of CD8 ϩ T cytotoxic and CD4 ϩ T helper subpopulations) and, to a lesser extent, CD45RA ϩ B lymphocytes and CD11c ϩ dendritic cells. CD68 ϩ macrophages did not localize within the infiltrates and were evenly dispersed along the infarct (scale barsϭ20 m). Mononuclear infiltration was significantly higher in the xenogeneic group at 1 week (C; nϭ4 per group) and 3 weeks (D; nϭ4 per group) after transplantation (*PϽ0.05 vs syngeneic and control groups; †PϽ0.05 vs syngeneic and allogeneic groups). GFP indicates green fluorescent protein.
were screened for circulating anti-donor antibodies. No alloreactive antibodies could be detected in any recipients of allogeneic CDCs at any time point. In contrast, in the xenogeneic setting, high titers of xenoreactive IgM antibodies were detected 1 and 3 weeks after transplantation, whereas a progressive increase in xenoreactive IgG antibodies was observed from week 1 to 3 ( Figure II in the online-only Data Supplement). The development of anti-donor antibodies in xenogeneic but not allogeneic recipients is consistent with the Ϸ8-fold-higher B-cell myocardial infiltration observed in the xenogeneic setting ( Figure 6C and 6D ).
Allogeneic CDCs Promote Endogenous Cardiac Regeneration
To investigate the mechanisms of benefit, we examined the fate of transplanted cells. Immunohistochemistry revealed that syngeneic and allogeneic CDCs resided primarily in the border zone and infarct scar; a subset of cells were found to be cycling in vivo 1 and 3 weeks after MI, as indicated by Ki-67 positivity and BrdU incorporation ( Figure V in the online-only Data Supplement). Rare events of cardiomyogenic (GFP ϩ /␣-Sarcomeric Actinin (␣SA) ϩ cells) and angiogenic (GFP ϩ /von Willebrand factor ϩ cells) differentiation of surviving CDCs could be detected in both the syngeneic and the allogeneic setting. Although most GFP ϩ /␣SA ϩ cells were small and exhibited an immature cardiomyocyte phenotype (Figure 7A ), mature GFP ϩ /␣SA ϩ cells structurally integrated into the host myocardium were occasionally seen ( Figure  7B ). In addition, GFP ϩ /von Willebrand factor ϩ were found to be incorporated in microvessels in the risk region ( Figure  7C ). These observations, which confirm previous reports, 7, 9, 15 demonstrate the multilineage potential of CDCs. However, these needle in the haystack instances of direct differentiation are likely too low to account for the observed robust functional benefit.
We thus attempted to quantify endogenous cardiac regeneration. Possible mechanisms include upregulation of cycling cardiomyocytes (arising either from resident cardiomyocyte cell cycle reentry 16 or from differentiation of endogenous stem cells 17 ), recruitment of endogenous progenitor cells to the site of cell transplantation, 6, 17, 18 and enhanced angiogenesis. 19 We found that syngeneic and allogeneic CDC therapy markedly enhanced the number of cycling host cardiomyocytes (GFP Ϫ /␣SA ϩ /Ki-67 ϩ and GFP Ϫ /␣SA ϩ /BrdU ϩ cells; Figure 7D , 7E, 7G, and 7H) 1 and 3 weeks after MI. However, the number of cycling host cardiomyocytes significantly decreased from 1 to 3 weeks, dropping to nearly undetectable levels at 6 months. Syngeneic and allogeneic CDC transplantation also recruited endogenous stem cells ( Figure 7F and 7I) ; the number of GFP Ϫ /c-Kit ϩ cells was increased in CDC-treated hearts compared with controls at 1 and 3 weeks after MI. As with resident cycling myocytes, the number of endogenous progenitors decreased as a function of time after treatment.
Finally, syngeneic and allogeneic CDC transplantation enhanced angiogenesis in the infarct border zone. Vessel density, identified by immunostaining for von Willebrand factor, was markedly increased 3 weeks after cell therapy compared with controls ( Figure 7J and 7K) . It should be noted that these endogenous reparative mechanisms were also mobilized in the control hearts. However, their magnitude was amplified (to similar degrees) by syngeneic and allogeneic CDC therapy.
Taken together, these data indicate that exogenous CDC administration stimulates activation of endogenous repair and regeneration pathways, confirming previous studies 5, 6 reporting that the majority of the observed benefit after cell therapy is attributable to indirect mechanisms rather than differentiation of transplanted cells. We thus quantified myocardial levels of beneficial paracrine factors in the infarct border zone. Western blot analysis revealed increased secretion of vascular endothelial growth factor, insulin-like growth factor-1, and hepatocyte growth factor in hearts treated with syngeneic and allogeneic CDCs compared with controls at days 1, 4, and 7 after MI ( Figure 8A-8D) . On the contrary, rats treated with xenogeneic CDCs had increased myocardial levels of these cytokines only at 1 day after MI, not at later time points ( Figure VI in the online-only Data Supplement). Three weeks after MI, no difference could be observed among groups. The data reveal that syngeneic and allogeneic CDCs are equivalent in their paracrine benefits, in both magnitude and time course, and that sustained increased levels of vascular endothelial growth factor, insulin-like growth factor-1, and hepatocyte growth factor, at least during the first week after cell transplantation, underlie the functional benefit. Our experimental design (transplantation of rCDCs into rat hearts and the use of antibodies that detect both human and rat cytokine isoforms) cannot elucidate whether the increased myocardial levels of these factors are attributable to direct secretion by transplanted cells, upregulation of host tissue humoral responses, 20 or both. Nevertheless, prior work shows that the release of paracrine factors directly from CDCs is substantial in the early posttransplantation period. 5
Discussion
We report a detailed spatiotemporal evaluation of the local and systemic immune responses after allogeneic CDC transplantation for myocardial repair. Allogeneic CDC transplantation without immunosuppression is safe and produces structural and functional benefits after MI by stimulating endogenous cardiac regeneration. This indirect mechanism of action, shared by syngeneic cells, explains why benefits persist despite the temporary engraftment of transplanted cells.
CDCs represent an attractive cell type for heart repair and regeneration. CDCs are clonogenic and exhibit multilineage potential, thus fulfilling key criteria for heart-derived stem cells. 15 Over the past 6 years, we have demonstrated that CDCs can improve cardiac function after MI in mice, 5, 7, 21 rats, 9, 22, 23 and pigs. 24, 25 Importantly, several independent laboratories worldwide have reproduced the published methodology and verified the identity and utility of CDCs. 26 -32 On the other hand, critiques of the cardiosphere methodology have appeared, 33, 34 but as we have pointed out in detailed rebuttals, 8, 15 these studies did not follow published protocols for CDC isolation and expansion, and the methodological variations likely explain the negative results. With regard to clinical translation, highly positive results from a proof-ofconcept clinical study using autologous CDCs, the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS; NCT00893360 3 ) trial, have recently been reported. 35 The avoidance of immunologic rejection renders autologous therapy attractive, but serious disadvantages dampen enthusiasm. Patient-specific tissue harvesting and cell processing result in a delay to therapy and introduce possible variations in cell potency related to patient age and disease. 4 Here, we tested the specific hypothesis that allogeneic CDCs are hypoimmunogenic in vivo and can survive in the infarcted myocardium for a critical period of time to stimulate endogenous reparative and regenerative pathways, resulting in sustained benefit. We found that allogeneic CDC transplantation without immunosuppression induces only a transient mild local immune reaction in a rat MI model. In the clinical setting, development of an immune response after allogeneic CDC delivery to the heart could theoretically lead to immunerelated myocardial damage (which, on the basis of our findings, would be unlikely because no foci of myocardial damage were detected even after xenogeneic CDC transplan- tation) and allosensitization of the cell recipient, which in turn could complicate repeat dosing with the same batch of cells (a problem that could easily be overcome by administering cells from different donors) and complicate future organ transplantation (if the CDC donor and organ donor share similar HLA haplotypes). We did not detect any circulating anti-donor antibodies after allogeneic CDC transplantation, implying that no significant increase in panel reactive antibodies would occur; the absence of such sensitization at baseline increases the likelihood of allograft survival. 36 In addition, the small inocula associated with CDC therapy (compared, for example, with the volumes used in blood transfusions) make sensitization of the recipient improbable. Nevertheless, the possibility of recipient allosensitization should be investigated in large animals as a prelude to studies in human subjects.
We have also shown that transient and rather paltry short-term cell survival suffices to produce dramatic lasting benefits. Despite lower cell engraftment, allogeneic CDC transplantation generates structural and functional benefits that are indistinguishable from syngeneic transplantation and persist 6 months after MI. The equivalence of allogeneic and syngeneic transplantation is not surprising once we recognize and accept the central paradox: Few, briefly present transplanted cells suffice to produce large, durable benefits by amplifying endogenous pathways of repair and regeneration rather than by directly generating new transplanted tissue. This indirect "amplifier effect," impressive as it may be, is not yet fully understood. 2 Even though we show that allogeneic CDCs stimulate host cardiomyocyte cycling, endogenous stem cell recruitment, and angiogenesis in the post-MI setting, it is unclear whether these phenomena can account for the totality of the observed benefit; other mechanisms could involve cytoprotection of the host tissue or modulation of inflammatory processes, resulting in better infarct healing. In addition, it is unclear how much of the benefit is attributable to the identified paracrine factors; insulin-like growth factor-1 and hepatocyte growth factor have been shown to mobilize resident cardiac stem cells, 37 whereas vascular endothelial growth factor is well known to stimulate angiogenesis. 38 Alternatively, other factors 39 may also play important roles. Identification of the appropriate cocktail of beneficial growth factors and incorporation into a formulation enabling sustained and controlled local release after cardiac delivery is a conceptually attractive approach. However, cell-mediated contact-dependent mechanisms may also contribute to the observed effects. 40 Regardless of the mechanism, in practice, the present work opens up a new treatment paradigm: CDCs could be grown in large numbers from allogeneic heart tissue in a central facility under strict quality control and banked for future use, enabling safe and effective myocardial repair in a timely, cost-efficient manner. Potential sources of allogeneic heart tissue include hearts explanted from organ donors but not used for transplantation, cadaveric hearts from the recently deceased, and surgical discards. Hearts obtained from organ donors (but not used for transplantation) have the inherent advantage that donors are, by definition, healthy and have been previously HLA typed and screened for infectious diseases, with the tissue maintained viable and sterile until processed. Hearts from organ donors after cardiac death are particularly attractive because they are rarely used for trans- plantation, although kidneys, liver, and pancreas are commonly used. 41 In 2008, there were 832 organ donors after cardiac death in the United States, and no hearts were used for cardiac transplantation 42 ; these hearts represent one pool from which source tissue can be obtained for allogeneic CDC culture. Cadaveric hearts from healthy, noninfectious donors also could be used; however, the tissue is not optimally stored, and samples would have to be obtained with low postmortem intervals. Surgical discards are yet another source option; although these specimens are more abundant, donors are apt to have an existing cardiac disorder or other comorbidities (which may or may not hamper cell quality).
Conclusions
We demonstrate that allogeneic CDC transplantation without immunosuppression is safe, promotes cardiac regeneration, and improves heart function in a rat MI model, mainly through stimulation of endogenous repair mechanisms. This indirect mechanism of action rationalizes the lasting benefit brought about by ephemeral transplanted cells in that the new tissue originates from the recipient rather than the donor. This work motivates the testing of allogeneic hCDCs as a potential clinical product for cellular cardiomyoplasty. 
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